Par Pharmaceutical Companies, Inc.  

(Public, NYSE:PRX)   Watch this stock  
Find more results for Par Pharmaceutical Companies, Inc

Officers and directors

Paul V. Campanelli
Chief Executive Officer, Director
Michael A. Tropiano
Chief Financial Officer, Executive Vice President, Director
Terrance John Coughlin
Chief Operating Officer
Thomas J. Haughey
Chief Administrative Officer, General Counsel, Director


United States - Map
+1-201-8024000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.

Related companies

* Delayed by up to 20 minutes -  Disclaimer